```html

Xanthoma Plana – A Complete Patient Guide

Overview

Xanthoma plana (also called “plane xanthoma” or “flat xanthoma”) is a rare skin disorder characterized by flat, yellow‑orange papules that most often appear on the face, neck, trunk, and extremities. These lesions are caused by the accumulation of lipid‑laden macrophages (called foam cells) within the superficial dermis.

Although it can affect anyone, plane xanthomas are most commonly associated with underlying lipid metabolism disorders (e.g., familial hypercholesterolemia) or hematologic diseases such as monoclonal gammopathy. The condition is considered uncommon; epidemiologic data are limited, but case series suggest a prevalence of less than 1 % among patients evaluated for dyslipidemia.<sup>1</sup>

Symptoms

Symptoms are usually cutaneous and may be subtle, which often delays diagnosis. The full spectrum includes:

• Flat, yellow‑orange papules – 1–5 mm in diameter, smooth, non‑raised (hence “plane”).
• Distribution – Commonly on the eyelids (erythema & telangiectatic), forehead, nasolabial folds, neck, trunk, and proximal limbs. In some cases, lesions may appear on the palms or soles.
• Itching or mild discomfort – Rare, but some patients report a pruritic sensation.
• Absence of pain – Lesions are typically painless.
• Associated systemic signs – When linked to a metabolic disorder, patients may have:
  • Early‑onset atherosclerotic cardiovascular disease.
  • History of tendon or tuberous xanthomas.
  • Fatigue, abdominal pain, or neuropathy if a plasma cell disorder is present.

Causes and Risk Factors

Primary (idiopathic) plane xanthoma

In a minority of patients, flat xanthomas appear without an identifiable systemic disease. The exact pathophysiology is uncertain, but hypotheses include localized lipid metabolism defects in the skin.

Secondary (associated) plane xanthoma

More often, plane xanthomas are a cutaneous marker of an underlying condition:

• Familial hypercholesterolemia (FH) – Autosomal‑dominant mutation in LDLR, APOB, or PCSK9 genes leading to markedly elevated LDL‑cholesterol.
• Secondary dyslipidemias – Diabetes mellitus, hypothyroidism, nephrotic syndrome, or chronic liver disease can raise serum lipids enough to trigger xanthoma formation.
• Hematologic disorders – Monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, or Waldenström macroglobulinemia.
• Other metabolic diseases – Lipoid proteinosis, cholestatic liver disease.

Risk factors therefore include any condition that raises circulating triglyceride‑rich or cholesterol‑rich lipoproteins, as well as genetic predispositions that impair lipid clearance.

Diagnosis

Diagnosing plane xanthoma involves a combination of clinical assessment, laboratory studies, and often a skin biopsy.

Clinical examination

• Visual inspection of the characteristic flat, yellow‑orange lesions.
• Dermatoscopy may reveal yellow‑white structureless areas without vascular patterns.

Laboratory tests

• Lipid profile – Total cholesterol, LDL‑C, HDL‑C, triglycerides. In FH, LDL‑C often >190 mg/dL in adults.
• Blood glucose & HbA1c – To rule out diabetes‑related dyslipidemia.
• Liver & kidney function tests – Detect nephrotic or cholestatic disease.
• Serum protein electrophoresis (SPEP) & immunofixation – Screen for monoclonal gammopathies.

Skin biopsy

When the diagnosis is uncertain, a 4‑mm punch biopsy of a representative lesion is performed. Histology shows:

• Superficial dermal infiltrate of lipid‑laden macrophages (foam cells).
• Absence of atypical melanocytes (helps differentiate from pigmented lesions).
• Occasional multinucleated giant cells.

Imaging (if systemic disease is suspected)

• Carotid duplex or coronary CT angiography for patients with high cardiovascular risk.
• Bone survey if multiple myeloma is a concern.

Treatment Options

Therapy focuses on two goals: (1) eliminating or reducing the cutaneous lesions and (2) treating any underlying systemic disease.

Addressing the underlying cause

• Statins – First‑line for LDL‑C reduction. High‑intensity regimens (e.g., atorvastatin 40–80 mg) can lower LDL by >50 %.<sup>2</sup>
• Ezetimibe – Added when statins alone are insufficient.
• PCSK9 inhibitors – Alirocumab or evolocumab for refractory FH; can reduce LDL‑C by up to 60 %.
• Fibrates & omega‑3 fatty acids – Useful when triglycerides are markedly elevated.
• Management of hematologic disease – Chemotherapy or targeted agents for MGUS/multiple myeloma per hematology guidelines.

Direct skin‑focused therapies

• Topical retinoids (tretinoin 0.05 %–0.1 %) – Promote epidermal turnover; modest improvement reported in case series.
• Laser therapy – Q‑switched Nd:YAG or pulsed‑dye lasers can reduce pigment and improve texture, though results are variable.
• Cryotherapy – Rarely used; may cause hypopigmentation.
• Excisional or shave biopsy – Considered for isolated, cosmetically bothersome lesions.

Lifestyle modifications

• Adopt a heart‑healthy diet – Emphasize fruits, vegetables, whole grains, lean protein, and limit saturated fat and trans‑fat.
• Engage in regular aerobic exercise – ≥150 min/week of moderate‑intensity activity lowers LDL and improves HDL.
• Maintain a healthy weight – BMI < 25 kg/m² reduces lipid burden.
• Quit smoking – Smoking accelerates atherosclerosis and can worsen xanthoma appearance.

Living with Xanthoma Plana

Daily skin care

• Use gentle, fragrance‑free cleansers; avoid harsh scrubbing.
• Apply a non‑comedogenic moisturizer with ceramides to maintain barrier function.
• Sun protection (SPF 30+). UV exposure may darken lesions and increase cosmetic concern.

Monitoring

• Schedule lipid panel checks every 3–6 months while on therapy.
• Annual dermatology review to assess lesion evolution.
• If you have a known hematologic condition, follow the recommended surveillance schedule for that disease.

Psychosocial aspects

The visible nature of plane xanthomas can cause anxiety or self‑esteem issues. Consider:

• Support groups (online or local) for patients with dyslipidemias.
• Counseling or cognitive‑behavioral therapy if you experience significant distress.
• Discuss cosmetic options (laser, topical retinoids) with a dermatologist experienced in pigmentary disorders.

Prevention

While idiopathic cases cannot be fully prevented, reducing the risk of secondary plane xanthomas is achievable:

• Screen for lipid disorders early – Family history of premature heart disease warrants lipid testing by age 20.
• Control diabetes and thyroid disease – Optimized glycemic and thyroid hormone levels lower lipid abnormalities.
• Limit alcohol excess – Alcohol can raise triglycerides dramatically.
• Maintain regular follow‑up with primary care or cardiology for known FH.

Complications

If left untreated, plane xanthomas themselves are benign, but they often signal systemic disease that can lead to serious outcomes:

• Accelerated atherosclerosis – Early myocardial infarction or stroke, especially in FH patients. Lifetime risk of coronary artery disease in untreated FH can exceed 50 % by age 50.<sup>3</sup>
• Pancreatitis – Extremely high triglyceride levels (>1,000 mg/dL) can trigger acute pancreatitis.
• Progression of hematologic malignancy – In MGUS, the risk of evolving to multiple myeloma is ~1 % per year.
• Cosmetic and psychosocial impact – Persistent lesions may cause body‑image concerns.

When to Seek Emergency Care

---

Sources:
1. Davis, M., & Whitaker, A. (2022). “Plane xanthomas: a review of clinical features and associations.” Dermatology Practical & Conceptual.
2. Grundy, S. M. et al. (2023). “2018 AHA/ACC Guideline on the Management of Blood Cholesterol.” Circulation.
3. Nordestgaard, B. G., et al. (2020). “Familial hypercholesterolaemia prevalence and impact on cardiovascular disease.” European Heart Journal.
Additional information retrieved from Mayo Clinic, CDC, NIH, WHO, and Cleveland Clinic portals (accessed June 2026). ```